Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease.

BACKGROUND Clostridium difficile is the most common infectious cause of colitis and has been increasingly diagnosed in hospitalized patients. The number of prescriptions for proton pump inhibitors (PPIs) has also increased significantly over time. Few studies have reported an association between C. difficile-associated disease (CDAD) and PPI use. AIM To assess the extent and appropriateness of PPI prescribing in patients diagnosed with C. difficile infection. METHODS We prospectively studied PPI prescriptions in 138 hospitalized patients diagnosed with C. difficile infection over a 4-month period. Clostridium difficile infections were diagnosed by the presence of C. difficile toxin in the stools. The appropriateness of prescriptions and relevant investigations were assessed by interview of patients and review of patient records. RESULTS Sixty-four percent (88 of 138) of all patients who developed C. difficile infections were on PPIs. A valid indication for PPIs therapy was not apparent in 63% of the patients. CONCLUSION There appears to be a widespread and inappropriate use of PPIs in hospital practice. Reduction of unnecessary PPIs use may be an additional strategy to reduce the incidence of this infection.

[1]  S. Poutanen,et al.  Clostridium difficile-associated diarrhea in adults , 2004, Canadian Medical Association Journal.

[2]  G E Bignardi,et al.  Risk factors for Clostridium difficile infection. , 1998, The Journal of hospital infection.

[3]  K. Tsimidis,et al.  Infection due to Clostridium difficile among elderly residents of a long-term-care facility. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  John K Marshall,et al.  Systematic Review of the Risk of Enteric Infection in Patients Taking Acid Suppression , 2007, The American Journal of Gastroenterology.

[5]  J. Hughes,et al.  Antibiotic-associated pseudomembranous colitis: an epidemiologic investigation of a cluster of cases. , 1982, The Journal of infectious diseases.

[6]  A. Hungin,et al.  Use of Proton Pump Inhibitors: An Exploration of the Attitudes, Knowledge and Perceptions of General Practitioners , 2005, Digestion.

[7]  Bette Jensen,et al.  A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile. , 2006, Archives of internal medicine.

[8]  M. Owings,et al.  Clostridium difficile Infection in Patients Discharged from US Short-stay Hospitals, 1996–2003 , 2006, Emerging Infectious Diseases.

[9]  N. Lurie,et al.  Omeprazole use at an urban county teaching hospital , 1995, Journal of General Internal Medicine.

[10]  G. Wolf-Klein,et al.  Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile-associated disease in nursing home patients. , 2005, Journal of the American Medical Directors Association.

[11]  A. Huang,et al.  Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case–control studies , 2004, Canadian Medical Association Journal.

[12]  M. Buckley,et al.  Appropriateness of gastric antisecretory therapy in hospital practice , 2003, Irish journal of medical science.

[13]  C. Kelly,et al.  Underlying Disease Severity as a Major Risk Factor for Nosocomial Clostridium difficile Diarrhea , 2002, Infection Control & Hospital Epidemiology.

[14]  A. Glatt,et al.  Clostridium difficile infection associated with antineoplastic chemotherapy: a review. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  Craig Williams,et al.  Occurrence and significance of gastric colonization during acid-inhibitory therapy. , 2001, Best practice & research. Clinical gastroenterology.

[16]  A. Blenkinsopp,et al.  Proton pump inhibitors: perspectives of patients and their GPs. , 2001, The British journal of general practice : the journal of the Royal College of General Practitioners.

[17]  A. Barkun,et al.  Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. , 2005, JAMA.

[18]  D. Birkett,et al.  Compliance with restrictions on the subsidized use of proton pump inhibitors in Australia. , 1998, British journal of clinical pharmacology.

[19]  S. Chapman,et al.  Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database , 1998, BMJ.

[20]  M. Stevenson,et al.  Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. , 2003, The Journal of antimicrobial chemotherapy.